Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study

AIMS: To evaluate the efficacy and safety of ultra rapid lispro (URLi) versus lispro in adults with type 1 diabetes in a 26‐week, treat‐to‐target, phase 3 trial. MATERIALS AND METHODS: After an 8‐week lead‐in to optimize basal insulin glargine or degludec, patients were randomized to double‐blind me...

Descripción completa

Detalles Bibliográficos
Autores principales: Klaff, Leslie, Cao, Dachuang, Dellva, Mary Anne, Tobian, Janet, Miura, Junnosuke, Dahl, Dominik, Lucas, Jean, Bue‐Valleskey, Juliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539952/
https://www.ncbi.nlm.nih.gov/pubmed/32488923
http://dx.doi.org/10.1111/dom.14100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539952/
https://www.ncbi.nlm.nih.gov/pubmed/32488923
http://dx.doi.org/10.1111/dom.14100

Ejemplares similares